`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`LUPIN LTD. and LUPIN PHARMACEUTICALS, INC.
`Petitioner,
`
`V.
`
`HORIZON THERAPEUTICS, INC.
`Patent Owner
`
`Case IPR20l6-00829
`
`Patent 9,095,559 B2
`
`AFFIDAVIT OF ROBERT V. CERWINSKI IN
`
`SUPPORT OF MOTION FOR PRO HAC VICE ADMISSION
`
`Mail Stop PATENT BOARD
`Patent Trial and Appeal Board
`United States Patent and Trademark Office
`
`P.O. Box 1450
`
`Alexandria, VA 22313-1450
`
`
`
`LUPIN EX. 1024
`
`l0f5
`
`1 of 5
`
`
`
`Case IPR20l6—0O829
`
`Patent 9,095,559 B2
`
`l.
`
`I, Robert V. Cerwinski, am more than twenty—one years of age, am
`
`competent to present this affidavit, and have personal knowledge of the facts set
`
`forth herein.
`
`2.
`
`This affidavit is given in support of Petitioners’ Motion for Pro Hac
`
`Vice Admission.
`
`3.
`
`4.
`
`I am a partner with the law firm of Goodwin Procter LLP.
`
`I am an experienced litigation attorney. I have been litigating patent
`
`cases for nearly nineteen years. I have been practicing law since 1997 and have
`
`extensive experience litigating patent infringement cases in many different courts
`
`across the United States.
`
`5.
`
`My experience in patent litigation matters includes patent jury trials,
`
`including opening statements, closing arguments, presentation of non-expert and
`
`expert—testimony, arguing Markman hearings, patent summary judgment
`
`proceedings, and other patent-related hearings and pleadings concerning, inter alia,
`
`patent validity and infringement issues. I have also represented clients’ appeals
`
`before the Court of Appeals for the Federal Circuit resulting from cases I tried and
`
`in other cases.
`
`6.
`
`I have an established familiarity with the subject matter at issue in this
`
`proceeding. I have reviewed the Petition and accompanying exhibits filed in this
`
`proceeding and all other papers associated with this proceeding. As part of this
`
`2of5
`
`2 of 5
`
`
`
`Case IPR20l6-00829
`
`Patent 9,095,559 B2
`
`proceeding, I have studied U.S. Patent 9,095,559 (“the ’559 patent”).
`
`I am also
`
`counsel of record in litigation in which the ’559 patent, as well as patents related to
`
`the ’559 patent, and other patents owned by Horizon Therapeutics, Inc. relating to
`
`methods of using glyceryl tri—[4—phenylbutyrate] to treat subjects with urea cycle
`
`disorders are being asserted. Horizon Therapeutics, Inc. v. Lupin Ltd., l—l5—cv-
`
`07624, l—l6—cv-04438(D.N.J.) (currently stayed).
`
`7.
`
`I am a member in good standing of the Bar of the State of New York
`
`and am admitted to practice before the United States District Court for the
`
`Southern District of New York and the United States Court of Appeals for the
`
`Federal Circuit.
`
`8.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`9.
`
`No application of mine for admission to practice before any court or
`
`administrative body has ever been denied.
`
`10. No sanctions or contempt citations have been imposed against me by
`
`any court or administrative body.
`
`ll.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
`
`12.
`
`I understand that I will be subject to the USPTO Code of Professional
`
`Conduct set forth in 37 C.P.R.§§ l0.l0l et seq. and disciplinary jurisdiction under
`
`3of5
`
`3 of 5
`
`
`
`Case IPR20l6—OO829
`
`Patent 9,095,559 B2
`
`37 C.P.R. §l l.l9(a).
`
`13.
`
`I have applied to appear pro hac vice in the following proceedings
`
`before the Office in the last three years: IPR20l5—0l566 (granted), lPR2015—Ol 571
`
`(action terminated before ruling), IPR20l5-01572 (action terminated before
`
`ruling), IPR20l 5-01570 (action terminated before ruling), lPR20l5-01733 (action
`
`terminated before ruling), and IPR20l5-01744 (action terminated before ruling),
`
`and IPR20l 6-01 614 (pending).
`
`Dated: December 21, 2016
`
`Respectfully submitted,
`
` . Cerwinski
`
`GOODVVIN PROCTER LLP
`
`Subscribed and sworn to
`__
`Ji-=~=~
`Before me this 5day of
`
`2-,,c:a,,.,<£»t»~ , 2015
`
`
`
`4of5
`
`4 of 5
`
`
`
`My commission expires:
`
`{[7 . 35; 263‘?
`
`Case IPR2016—0O829
`
`Patent 9,095,559 B2
`
`50f5
`
`5 of 5